Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

29.58 0.14 +0.48%
Market cap
$167.8B
P/E
38.9×
Fwd P/E
12.2×
Dividend yield
5.81%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

10.59% 8.87% 8.28% 4.97%
Piotroski F-Score
7 6 5 6
ROA
4.59% 3.69% 3.60% 2.13%
ROIC
6.13% 6.45% 6.41% 6.30%
Return on Tangible Assets
33.65% 30.80% 26.87% 15.62%
Average Days of Receivables
82.90 69.26 72.55 71.57
Free Cash Flow per Share
1.83 1.60 1.67 1.93
Free Cash Flow
10,376.00 9,075.00 9,483.00 10,985.00
Other line items

Show all line items

Columns are period end dates